Given the high risk of developing BC, the NCCN guidelines suggest that women with TP53 PV/LPVs should undergo clinical breast examination every 6–12 months starting at the age of 20, annual breast MRI screening with contrast from 20 to 75 years, and mammography with consideration of tomosynthesis from 30 to 75 years. Here, TP53 is linked to breast cancer.